|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 22365 |
FusionGeneSummary for MPO_ACSL1 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: MPO_ACSL1 | Fusion gene ID: 22365 | Hgene | Tgene | Gene symbol | MPO | ACSL1 | Gene ID | 4353 | 2180 |
| Gene name | myeloperoxidase | acyl-CoA synthetase long chain family member 1 | |
| Synonyms | - | ACS1|FACL1|FACL2|LACS|LACS1|LACS2 | |
| Cytomap | 17q22 | 4q35.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | myeloperoxidase | long-chain-fatty-acid--CoA ligase 1LACS 1LACS 2acyl-CoA synthetase 1fatty-acid-Coenzyme A ligase, long-chain 1fatty-acid-Coenzyme A ligase, long-chain 2lignoceroyl-CoA synthaselong-chain acyl-CoA synthetase 1long-chain acyl-CoA synthetase 2long-c | |
| Modification date | 20180523 | 20180522 | |
| UniProtAcc | P05164 | P33121 | |
| Ensembl transtripts involved in fusion gene | ENST00000340482, ENST00000225275, ENST00000578493, | ENST00000454703, ENST00000515030, ENST00000281455, ENST00000507295, ENST00000437665, ENST00000504342, ENST00000504900, ENST00000513317, | |
| Fusion gene scores | * DoF score | 7 X 4 X 2=56 | 2 X 2 X 2=8 |
| # samples | 6 | 2 | |
| ** MAII score | log2(6/56*10)=0.0995356735509144 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(2/8*10)=1.32192809488736 | |
| Context | PubMed: MPO [Title/Abstract] AND ACSL1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | MPO | GO:0034374 | low-density lipoprotein particle remodeling | 10772654 |
| Hgene | MPO | GO:0042744 | hydrogen peroxide catabolic process | 10772654|11907569 |
| Hgene | MPO | GO:0055114 | oxidation-reduction process | 10772654 |
| Tgene | ACSL1 | GO:0001676 | long-chain fatty acid metabolic process | 22022213 |
| Tgene | ACSL1 | GO:0008610 | lipid biosynthetic process | 21242590 |
| Tgene | ACSL1 | GO:0044539 | long-chain fatty acid import | 22022213 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | BI020982 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3UTR | ENST00000340482 | ENST00000454703 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000340482 | ENST00000515030 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000340482 | ENST00000281455 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000340482 | ENST00000507295 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000340482 | ENST00000437665 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000340482 | ENST00000504342 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-intron | ENST00000340482 | ENST00000504900 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000340482 | ENST00000513317 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000225275 | ENST00000454703 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000225275 | ENST00000515030 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000225275 | ENST00000281455 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000225275 | ENST00000507295 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000225275 | ENST00000437665 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000225275 | ENST00000504342 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-intron | ENST00000225275 | ENST00000504900 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000225275 | ENST00000513317 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000578493 | ENST00000454703 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000578493 | ENST00000515030 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000578493 | ENST00000281455 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000578493 | ENST00000507295 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000578493 | ENST00000437665 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000578493 | ENST00000504342 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-intron | ENST00000578493 | ENST00000504900 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
| intron-3UTR | ENST00000578493 | ENST00000513317 | MPO | chr17 | 56355832 | + | ACSL1 | chr4 | 185678233 | - |
Top |
FusionProtFeatures for MPO_ACSL1 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| MPO | ACSL1 |
| Part of the host defense system of polymorphonuclearleukocytes. It is responsible for microbicidal activity against awide range of organisms. In the stimulated PMN, MPO catalyzes theproduction of hypohalous acids, primarily hypochlorous acid inphysiologic situations, and other toxic intermediates that greatlyenhance PMN microbicidal activity. {ECO:0000269|PubMed:9922160}. | Activation of long-chain fatty acids for both synthesisof cellular lipids, and degradation via beta-oxidation.Preferentially uses palmitoleate, oleate and linoleate. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for MPO_ACSL1 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for MPO_ACSL1 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for MPO_ACSL1 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | MPO | P05164 | DB00244 | Mesalazine | Myeloperoxidase | small molecule | approved |
| Hgene | MPO | P05164 | DB00535 | Cefdinir | Myeloperoxidase | small molecule | approved |
| Hgene | MPO | P05164 | DB00583 | L-Carnitine | Myeloperoxidase | small molecule | approved|investigational |
| Hgene | MPO | P05164 | DB01065 | Melatonin | Myeloperoxidase | small molecule | approved|nutraceutical|vet_approved |
Top |
RelatedDiseases for MPO_ACSL1 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | MPO | C0035126 | Reperfusion Injury | 6 | CTD_human |
| Hgene | MPO | C0021368 | Inflammation | 5 | CTD_human |
| Hgene | MPO | C0009324 | Ulcerative Colitis | 3 | CTD_human |
| Hgene | MPO | C0398595 | Myeloperoxidase Deficiency | 3 | CTD_human;ORPHANET;UNIPROT |
| Hgene | MPO | C0003873 | Rheumatoid Arthritis | 2 | CTD_human |
| Hgene | MPO | C0023891 | Liver Cirrhosis, Alcoholic | 2 | CTD_human |
| Hgene | MPO | C0001969 | Alcoholic Intoxication | 1 | PSYGENET |
| Hgene | MPO | C0002395 | Alzheimer's Disease | 1 | CTD_human |
| Hgene | MPO | C0005695 | Bladder Neoplasm | 1 | CTD_human |
| Hgene | MPO | C0006111 | Brain Diseases | 1 | CTD_human |
| Hgene | MPO | C0007222 | Cardiovascular Diseases | 1 | CTD_human |
| Hgene | MPO | C0007786 | Brain Ischemia | 1 | CTD_human |
| Hgene | MPO | C0009319 | Colitis | 1 | CTD_human |
| Hgene | MPO | C0011609 | Drug Eruptions | 1 | CTD_human |
| Hgene | MPO | C0011853 | Diabetes Mellitus, Experimental | 1 | CTD_human |
| Hgene | MPO | C0022593 | Keratosis | 1 | CTD_human |
| Hgene | MPO | C0022658 | Kidney Diseases | 1 | CTD_human |
| Hgene | MPO | C0024115 | Lung diseases | 1 | CTD_human |
| Hgene | MPO | C0024121 | Lung Neoplasms | 1 | CTD_human |
| Hgene | MPO | C0028797 | Occupational Diseases | 1 | CTD_human |
| Hgene | MPO | C0030305 | Pancreatitis | 1 | CTD_human |
| Hgene | MPO | C0032927 | Precancerous Conditions | 1 | CTD_human |
| Hgene | MPO | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Hgene | MPO | C0036982 | Shock, Hemorrhagic | 1 | CTD_human |
| Hgene | MPO | C0040954 | Infection by Trichuris trichiura | 1 | CTD_human |
| Hgene | MPO | C0042109 | Urticaria | 1 | CTD_human |
| Hgene | MPO | C0242184 | Hypoxia | 1 | CTD_human |
| Hgene | MPO | C0993582 | Arthritis, Experimental | 1 | CTD_human |
| Hgene | MPO | C1269683 | Major Depressive Disorder | 1 | CTD_human |
| Hgene | MPO | C2239176 | Liver carcinoma | 1 | CTD_human |
| Hgene | MPO | C2609414 | Acute kidney injury | 1 | CTD_human |
| Tgene | ACSL1 | C0011853 | Diabetes Mellitus, Experimental | 1 | CTD_human |
| Tgene | ACSL1 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Tgene | ACSL1 | C0024667 | Animal Mammary Neoplasms | 1 | CTD_human |
| Tgene | ACSL1 | C0024668 | Mammary Neoplasms, Experimental | 1 | CTD_human |
| Tgene | ACSL1 | C0028754 | Obesity | 1 | CTD_human |
| Tgene | ACSL1 | C0993582 | Arthritis, Experimental | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|